How long do you continue immunotherapy (ie rituximab) in patients with NMDAR encephalitis with initially severe disease but a good trajectory of recovery?

Assuming there may be no evidence of teratoma on transvaginal U/S and or other modalities of examination (in females, some cases are described that show abnormalities in the ovary ONLY following HPE upon oophorectomy) and since there is always the risk of recurrence even with bilateral oophorectomy,...